Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population

  • Marco R. Scipione
  • John Papadopoulos


Viral infections are a global public health problem and can contribute significantly to patient morbidity and mortality. It is estimated that there are 350 million people worldwide who are infected with hepatitis B virus and 17,000 new cases per year of hepatitis C are identified (Wasley et al., MMWR Morb Mortal Wkly Rep 57(SS-2):1–24, 2008). Herpes viruses are common, with an estimated seroprevalence of 50% for herpes simplex virus type-1 and 20% herpes simplex virus type-2 seroprevalence among adults in the United States (Piret and Boivin, Antimicrob Agents Chemother 55(2):459–472, 2011). Influenza infections worldwide lead to serious morbidity and have been associated with thousands of deaths each year; 18,500 deaths were attributed to 2009 influenza A H1N1 pandemic alone (MMWR Morb Mortal Wkly Rep 59(33):1057–1089, 2010; Dawood et al., Lancet Infect Dis 12(9):687–695, 2012). It is imperative that clinicians have an intimate knowledge of any medication used in their practice and a working knowledgebase of pharmacokinetics and pharmacodynamics is especially true in the discipline of infectious diseases. This chapter provides a detail review of pharmacokinetic and pharmacodynamic parameters of antiviral agents utilized to treat select viral infections in patients undergoing transplantation.


Antiviral agents Pharmacokinetics Pharmacodynamics Herpes Hepatitis Influenza 


  1. 1.
    Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(SS-2):1–24.Google Scholar
  2. 2.
    Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459–72.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057–89.Google Scholar
  4. 4.
    Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng P-Y, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687–95.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Information P. Zovirax (Acyclovir). Research Triangle Park: GlaxoSmithKline; 2007.Google Scholar
  6. 6.
    Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med. 1982;73(1A):7–13.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47(1):153–205.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet. 1983;8(3):187–201.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29–37.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982;73(1A):186–92.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Laskin OL, Longstreth JA, Whelton A, Krasny HC, Keeney RE, Rocco L, et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med. 1982;73(1A):197–201.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Laskin OL, Longstreth JA, Saral R, de Miranda P, Keeney R, Lietman PS. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. Antimicrob Agents Chemother. 1982;21(3):393–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med. 1982;73(1A):202–4.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Seth SK, Visconti JA, Hebert LA, Krasny HC. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. Clin Pharm. 1985;4(3):320–2.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Lycke J, Andersen O, Svennerholm B, Appelgren L, Dahlof C. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother. 1989;24(6):947–54.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Hung SO, Patterson A, Rees PJ. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol. 1984;68(3):192–5.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol. 1998;179(4):846–51.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Information P. Zovirax (Acyclovir Ointment) 5%. Research Triangle Park: GlaxoSmithKline Inc; 2001.Google Scholar
  19. 19.
    Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother. 2001;45(1):150–7.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hintz M, Connor JD, Spector SA, Blum MR, Keeney RE, Yeager AS. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Am J Med. 1982;73(1A):210–4.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Information P. Valtrex (Valacyclovir). Research Triangle Park: GlaxoSmithKline; 2011.Google Scholar
  22. 22.
    Wang LH, Schultz M, Weller S, Smiley ML, Blum MR. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother. 1996;40(1):80–5.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antivir Res. 1995;28(4):281–90.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39(12):2759–64.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54(6):595–605.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Kambhampati G, Pakkivenkata U, Kazory A. Valacyclovir neurotoxicity can be effectively managed by hemodialysis. Eur J Neurol. 2011;18(3):e33.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother. 2004;53(6):899–901.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Rolan P. Pharmacokinetics of new antiherpetic agents. Clin Pharmacokinet. 1995;29(5):333–40.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Lycke J, Malmestrom C, Stahle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003;47(8):2438–41.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010;54(3):1146–51.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Kimberlin DW, Jacobs RF, Weller S, van der Walt JS, Heitman CK, Man CY, et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin Infect Dis. 2010;50(2):221–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721–9.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Cheng YC, Grill SP, Dutschman GE, Nakayama K, Bastow KF. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem. 1983;258(20):12460–4.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther. 1995;17(3):425–32.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Zhou XJ, Gruber W, Demmler G, Jacobs R, Reuman P, Adler S, et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Antimicrob Agents Chemother. 1996;40(9):2202–5.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    DeArmond B. Future directions in the management of cytomegalovirus infections. J Acquir Immune Defic Syndr. 1991;4(Suppl 1):S53–6.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1995;171(6):1431–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Information P. Zirgan (Ganciclovir ophthalmic gel) 0.15%. Tampa: Sirion Therapeutics, Inc; 2009.Google Scholar
  40. 40.
    Information P. Vitrasert (Ganciclovir Intravitreal Implant). Irvine: Chiron Vision Corporation; 1997.Google Scholar
  41. 41.
    Lake KD, Fletcher CV, Love KR, Brown DC, Joyce LD, Pritzker MR. Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother. 1988;32(12):1899–900.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Jacobson MA, de Miranda P, Cederberg DM, Burnette T, Cobb E, Brodie HR, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother. 1987;31(8):1251–4.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis. 1988;10(Suppl 3):S507–14.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH Jr. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986;40(3):281–6.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs. 2009;11(5):309–21.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clin Pharmacol Ther. 1993;53(1):15–21.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Frenkel LM, Capparelli EV, Dankner WM, Xu J, Smith IL, Ballow A, et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis. 2000;182(6):1616–24.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Martin JC, Dvorak CA, Smee DF, Matthews TR, Verheyden JP. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983;26(5):759–61.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37(2):167–76.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Information P. Valcyte (Valganciclovir). Nutley: Roche Laboratories Inc; 2001.Google Scholar
  51. 51.
    Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999;39(8):800–4.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44(10):2811–5.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet. 2005;44(5):495–507.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002;72(2):142–50.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Acosta EP, Brundage RC, King JR, Sanchez PJ, Sood S, Agrawal V, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther. 2007;81(6):867–72.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant. 2007;11(3):301–5.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Zhang D, Lapeyraque AL, Popon M, Loirat C, Jacqz-Aigrain E. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol. 2003;18(9):943–8.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Kimberlin DW, Acosta EP, Sanchez PJ, Sood S, Agrawal V, Homans J, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197(6):836–45.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992;92(2A):3S–7S.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989;33(5):742–5.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Taburet AM, Katlama C, Blanshard C, Zorza G, Gazzard D, Dohin E, et al. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. Antimicrob Agents Chemother. 1992;36(9):1821–4.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Fletcher CV, Collier AC, Rhame FS, Bennett D, Para MF, Beatty CC, et al. Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob Agents Chemother. 1994;38(3):604–7.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Sjovall J, Bergdahl S, Movin G, Ogenstad S, Saarimaki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1989;33(7):1023–31.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Sjovall J, Karlsson A, Ogenstad S, Sandstrom E, Saarimaki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther. 1988;44(1):65–73.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Lee MY, Kim KS, Lee WK. Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. Ocul Immunol Inflamm. 2011;19(3):212–3.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Wong R, Pavesio CE, Laidlaw DA, Williamson TH, Graham EM, Stanford MR. Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology. 2010;117(3):556–60.CrossRefGoogle Scholar
  67. 67.
    Ausayakhun S, Watananikorn S, Ngamtiphakorn S, Prasitsilp J. Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS. J Med Assoc Thail. 2005;88(1):103–7.Google Scholar
  68. 68.
    Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, et al. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(4):350–7.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36(2):127–43.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Safrin S, Cherrrington J, Jaffe HS. Clinical uses of Cidofovir. Rev Med Virol. 1997;7:145–56.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995;39(6):1247–52.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(4):339–44.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999;65(1):21–8.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Mackey MC. Intravesicular cidofovir for the treatment of polyomavirus-associated hemorrhagic cystitis. Ann Pharmacother. 2012;46(3):442–6.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Muluneh B, Dean A, Armistead P, Khan T. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. J Oncol Pharm Pract. 2013;19(2):181–5PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Skevaki CL, Galani IE, Pararas MV, Giannopoulou KP, Tsakris A. Treatment of viral conjunctivitis with antiviral drugs. Drugs. 2011;71(3):331–47.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31(1):1–8.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Weinberg A, Bate BJ, Masters HB, Schneider SA, Clark JC, Wren CG, et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1992;36(9):2037–8.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Pue MA, Pratt SK, Fairless AJ, Fowles S, Laroche J, Georgiou P, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother. 1994;33(1):119–27.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Fowles SE, Pierce DM, Prince WT, Staniforth D. The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol. 1992;43(5):513–6.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther. 1994;55(4):418–26.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Information P. Denavir (Penciclovir cream 1%). Parsippany: Novartis Consumer Health Inc; 2002.Google Scholar
  83. 83.
    Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, et al. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica. 1994;24(4):357–68.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, et al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol. 1994;34(12):1199–207.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14(1):35–51.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Dourmashkin RR, Tyrrell DA. Electron microscopic observations on the entry of influenza virus into susceptible cells. J Gen Virol. 1974;24(1):129–41.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Skehel JJ, Hay AJ, Armstrong JA. On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol. 1978;38(1):97–110.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Krumbholz A, Schmidtke M, Bergmann S, Motzke S, Bauer K, Stech J, et al. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol. 2009;90(Pt 4):900–8.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Higgins RR, Eshaghi A, Burton L, Mazzulli T, Drews SJ. Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto. J Clin Virol. 2009;44(1):91–3.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, Stephens MK, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981;94(4 pt 1):454–8.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet. 2002;41(4):261–309.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother. 1985;28(2):216–21.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Betts RF. Amantadine and rimantadine for the prevention of influenza A. Semin Respir Infect. 1989;4(4):304–10.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 1989;159(3):430–5.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother. 1995;29(3):299–310.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363–73.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37(6):471–84.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26(11):787–801.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis. 2002;186(8):1074–80.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors – a review. Antivir Res. 2000;47(1):1–17.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Pizzorno A, Abed Y, Boivin G. Influenza drug resistance. Semin Respir Crit Care Med. 2011;32(4):409–22.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Moscona A. Oseltamivir resistance – disabling our influenza defenses. N Engl J Med. 2005;353(25):2633–6.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284–92.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364(9436):759–65.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother. 2005;49(11):4515–20.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Wattanagoon Y, Stepniewska K, Lindegardh N, Pukrittayakamee S, Silachamroon U, Piyaphanee W, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):945–52.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Robson R, Buttimore A, Lynn K, Brewster M, Ward P. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2006;21(9):2556–62.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol. 2005;59(5):598–601.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowski R, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs. 2001;3(3):229–36.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Woods JM, Bethell RC, Coates JA, Healy N, Hiscox SA, Pearson BA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza a and B viruses in vitro. Antimicrob Agents Chemother. 1993;37(7):1473–9.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Cass LM, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1):21–31.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1):1–11.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19(5):410–7.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Rivkin AM. Adefovir dipivoxil in the treatment of chronic hepatitis B. Ann Pharmacother. 2004;38(4):625–33.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12(3):355–62.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49(5 Suppl):S174–84.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39(6):1085–9.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125(2):292–7.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Kearney BP, Ramanathan S, Cheng AK, Ebrahimi R, Shah J. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. J Clin Pharm Ther. 2005;45(8):935–40.Google Scholar
  120. 120.
    Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995;39(11):2401–5.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Shiffman ML, Pol S, Rostaing L, Schiff E, Thabut D, Zeuzem S, et al. Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. J Clin Pharm Ther. 2011;51(9):1293–301.Google Scholar
  122. 122.
    Sokal EM, Kelly D, Wirth S, Mizerski J, Dhawan A, Frederick D. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharm Ther. 2008;48(4):512–7.Google Scholar
  123. 123.
    Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother. 1998;42(12):3200–8.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Gish RG. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin Liver Dis. 2005;25(Suppl 1):29–39.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs. 2003;12(4):683–8.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48(9):3498–507.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Yan JH, Bifano M, Olsen S, Smith RA, Zhang D, Grasela DM, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol. 2006;46(11):1250–8.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Sims KA, Woodland AM. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy. 2006;26(12):1745–57.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Cammack N, Rouse P, Marr CL, Reid PJ, Boehme RE, Coates JA, et al. Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol. 1992;43(10):2059–64.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Information P. Epivir-HBV (Lamivudine). Research Triangle Park: GlaxoSmithKline; 2011.Google Scholar
  132. 132.
    Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36(1):41–66.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992;6(12):1471–5.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995;35(12):1174–80.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40(6):1514–9.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 1998;46(1):21–7.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol. 1998;54(4):363–6.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178(5):1327–33.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis. 1996;174(1):16–25.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother. 2003;37(6):849–59.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy. 2009;29(10):1212–27.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31(Suppl 1):111–6.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010;52(4):493–500.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51(1):73–80.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45(10):2733–9.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Delaney WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50(7):2471–7.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42(9):2380–4.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet. 2006;45(11):1115–24.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2004;48(1):124–9.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Kim JJ, Culley CM, Mohammad RA. Telaprevir: an oral protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm. 2012;69(1):19–33.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011;45(5):639–48.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Welsch C, Domingues FS, Susser S, Antes I, Hartmann C, Mayr G, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol. 2008;9(1):R16.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138(2):447–62.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46(3):640–8.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46(3):631–9.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131(4):997–1002.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459–68 e1; quiz e14.CrossRefGoogle Scholar
  159. 159.
    Information P. Incivek (Telaprevir). Cambridge, MA: Vertex Pharmaceuticals Inc; 2012.Google Scholar
  160. 160.
    Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006;50(3):1013–20.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436(7053):939–45.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Klibanov OM, Vickery SB, Olin JL, Smith LS, Williams SH. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. 2012;32(2):173–90.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48(6):1769–78.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods. 2008;153(2):156–62.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother. 2005;49(10):4305–14.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 2005;280(44):36784–91.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011;45(9):1085–93.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O’Mara E, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51(9):619–28.PubMedCrossRefPubMedCentralGoogle Scholar
  169. 169.
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007;132(4):1270–8.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Kempf DJ, Klein C, Chen HJ, Klein LL, Yeung C, Randolph JT, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother. 2007;18(3):163–7.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63(7–8):832–42.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177(4050):705–6.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, et al. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973;70(4):1174–8.PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000;118(2):346–55.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282(5386):103–7.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37(6):1343–50.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37(6):1351–8.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126(3):703–14.PubMedCrossRefPubMedCentralGoogle Scholar
  179. 179.
    Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol. 2000;49(5):417–21.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 1998;46(6):563–70.PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999;43(10):2451–6.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Information P. Copegus (Ribavirin). South San Francisco: Genentech USA Inc; 2011.Google Scholar
  183. 183.
    Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–63.PubMedCrossRefPubMedCentralGoogle Scholar
  184. 184.
    Information P. Virazole (Ribavirin for inhalation solution). Aliso Viejo: Valeant Pharmaceuticals; 2008.Google Scholar
  185. 185.
    Information P. Rebetol (Ribavirin). Kenilworth: Schering Plough Corporation; 2003.Google Scholar
  186. 186.
    Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307–36.PubMedCrossRefPubMedCentralGoogle Scholar
  187. 187.
    Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, et al. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. J Viral Hepat. 2012;19(Suppl 1):33–6.PubMedCrossRefPubMedCentralGoogle Scholar
  188. 188.
    Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266(10):1375–83.PubMedCrossRefPubMedCentralGoogle Scholar
  189. 189.
    Sen GC. Viruses and interferons. Annu Rev Microbiol. 2001;55:255–81.PubMedCrossRefPubMedCentralGoogle Scholar
  190. 190.
    Tamir A, Jordan WJ, Ritter M, Habib N, Lechler RI, Foster GR, et al. Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity. Clin Exp Immunol. 2005;142(3):471–80.PubMedPubMedCentralGoogle Scholar
  191. 191.
    Barnes E, Salio M, Cerundolo V, Medlin J, Murphy S, Dusheiko G, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother. 2004;48(9):3382–9.PubMedPubMedCentralCrossRefGoogle Scholar
  192. 192.
    Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis. 2005;5(5):296–304.PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003;37(3):610–21.PubMedCrossRefPubMedCentralGoogle Scholar
  194. 194.
    Luik A, Knapp S, Thursz M, Thomas HC, Schlaak JF. Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. J Interf Cytokine Res. 2004;24(10):585–93.CrossRefGoogle Scholar
  195. 195.
    Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19(5):390–9.PubMedCrossRefPubMedCentralGoogle Scholar
  196. 196.
    Rumi M, Aghemo A, Prati GM. Comparative trials of peginterferon alpha2a and peginterferon alpha2b for chronic hepatitis C. J Viral Hepat. 2012;19(Suppl 1):37–41.PubMedCrossRefPubMedCentralGoogle Scholar
  197. 197.
    Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin N Am. 2010;39(3):649–58.CrossRefGoogle Scholar
  198. 198.
    Information P. Pegintron (Peg-interferon-alfa-2b). Whitehouse Station: Merck & Co, Inc; 2011.Google Scholar
  199. 199.
    Information P. Pegasys (Peg-interferon-alfa-2a). South San Francisco: Genentech USA, Inc; 2011.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Marco R. Scipione
    • 1
  • John Papadopoulos
    • 2
  1. 1.Department of PharmacyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Pharmacy, Division of PharmacotherapyNYU Langone Medical CenterNew YorkUSA

Personalised recommendations